NanoViricides, Inc. Submits Pre-IND Briefing Document for its Anti-Influenza Drug, FluCide™, to the US FDA

Published: Jan 31, 2012

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has submitted a pre-IND briefing document to the US FDA. This submission provides the required information for the Company’s highly effective anti-influenza drug candidate, FluCide™, in support of a pre-IND Meeting. The Company anticipates that the pre-IND Meeting would take place in March-April 2012. The actual meeting date will be assigned by the FDA.

Back to news